This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ventas, Inc. is a healthcare real estate investment trust (REIT) that is primarily engaged in acquisition and ownership of senior housing, R&I and healthcare properties, and leasing them to unaffiliated tenants or operating them through independent third-party managers. Ventas offers MOB management, leasing, marketing, facility development and advisory services to well-rated hospitals and health systems throughout the United States through its ownership interest in PMB Real Estate Services LLC and the company’s subsidiary, Lillibridge Healthcare Services, Inc. It also makes secured and non-mortgage loans and other investments relating to senior housing and healthcare properties or operators.
Liberty Property (LPT) Q4 FFO Tops, Gives Sears Impact Update
by Zacks Equity Research
Liberty Property's (LPT) Q4 results highlight rent escalation in industrial portfolio. It plans an aggressive push toward concluding its repositioning efforts and issued the Sears bankruptcy impact.
Ventas (VTR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While higher supply of senior housing assets may impede Ventas' (VTR) Q4 performance, the company's solid medical office building (MOB) portfolio remains a positive.
Digital Realty (DLR) Q4 FFO Tops Estimates, Revenues Up Y/Y
by Zacks Equity Research
Digital Realty Trust's (DLR) Q4 results highlight decent demand for data-center facilities, encouraging the company to reaffirm its core FFO projections for the current year.
Alexandria (ARE) Q4 FFO & Revenues Miss Estimates, Up Y/Y
by Zacks Equity Research
Alexandria Real Estate Equities' (ARE) Q4 results highlight increase in rental rate. However, expenses tied to rental operations and interests were higher in the quarter.
HT vs. VTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
HT vs. VTR: Which Stock Is the Better Value Option?
Why Trending Outpatient Care is a Boon for Healthcare REITs
by Devyani Chamria
Amid shift of care to low-cost setting, medical office buildings (MOBs) and outpatient facilities have been creating opportunities for healthcare REITs to park their money.
HPT or VTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HPT vs. VTR: Which Stock Is the Better Value Option?
Why Is Ventas (VTR) Up 8% Since Last Earnings Report?
by Zacks Equity Research
Ventas (VTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is it Wise to Hold Ventas (VTR) Stock in Your Portfolio Now?
by Zacks Equity Research
Ventas (VTR) is expected to grow on the back of accretive investments in its medical office and life science real estate portfolio. Yet, escalating supply of senior housing assets is a concern.
Lamar Advertising (LAMR) Q3 AFFO Tops, Revenues Miss Estimates
by Zacks Equity Research
Lamar Advertising's (LAMR) revenues miss the Zacks Consensus Estimate in Q3. Nonetheless, the bottom line witnesses year-over-year growth.
CORR or VTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CORR vs. VTR: Which Stock Is the Better Value Option?
W. P. Carey Buys Automotive Dealership Portfolio for $33M
by Zacks Equity Research
W. P. Carey (WPC) expands in the Netherlands with the acquisition of a portfolio of four automotive retail and service sites that is leased to Van Mossel for 17 years.
Outfront Media (OUT) Beats Q3 FFO and Revenue Estimates
by Zacks Equity Research
Outfront Media's (OUT) third-quarter 2018 FFO and revenues beat estimates. While billboard revenues boosted results, escalating operating expenses remains a drag.
Ventas' (VTR) Q3 FFO Surpasses Estimates, Revenues Up Y/Y
by Zacks Equity Research
Ventas' (VTR) third-quarter results highlight strength in the company's triple net leased and office portfolio.
Ventas (VTR) Tops Q3 FFO and Revenue Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 2.06% and 3.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Key Factors to Impact Ventas' (VTR) Earnings This Season
by Zacks Equity Research
Higher interest rates may impede Ventas' (VTR) Q3 bottom line. Nonetheless, a strong senior housing portfolio remains the silver lining.
HT or VTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HT vs. VTR: Which Stock Is the Better Value Option?
Equity Residential to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Equity Residential's (EQR) Q3 performance is likely to be driven by strong rental housing demand. However, higher supply is likely to curb growth tempo.
Crown Castle (CCI) to Post Q3 Earnings: What Lies Ahead?
by Zacks Equity Research
Crown Castle International's (CCI) Q3 top-line growth will likely be hindered by rapid adoption of the Voice over WiFi network by mobile handset manufacturers and wireless carriers.
SL Green (SLG) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
SL Green Realty (SLG) will likely gain from its portfolio-repositioning and asset disposition efforts in Q3. Yet, fall in rental revenues may persist in the near term.
Key Factors to Impact Prologis' (PLD) Earnings This Season
by Zacks Equity Research
Prologis' (PLD) Q3 results likely to reflect healthy fundamentals of the industrial real estate market backed by an improving economy and strengthening e-commerce market.
Here's Why You Should Hold Ventas in Your Portfolio Now
by Zacks Equity Research
While a diversified portfolio insulates Ventas' (VTR) performance from any unfavorable market swings, elevated supply of senior housing assets could impact its pricing power in the near future.
Ventas Enhances New York Portfolio With Battery Park Buyout
by Zacks Equity Research
Amid stiff competition with healthcare operators, Ventas (VTR) cracks an attractive deal to acquire Battery Park from Brookdale for around $194 million.
HT or VTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HT vs. VTR: Which Stock Is the Better Value Option?
Will Rising Healthcare Spending Aid HCP This Earnings Season?
by Zacks Equity Research
HCP Q2 results likely to reflect benefit from shedding of Brookdale assets. However, rising interest rates remains a concern.